Legend Biotech (LEGN) Share-based Compensation (2020 - 2025)

Legend Biotech (LEGN) has 6 years of Share-based Compensation data on file, last reported at $15.0 million in Q3 2025.

• In Q3 2025, Share-based Compensation fell 0.64% year-over-year to $15.0 million; the TTM figure through Sep 2025 stood at $64.8 million (down 4.65% YoY), while the FY2022 annual figure was $34.3 million, up 70.34% from the prior year.
• Share-based Compensation retreated to $15.0 million in Q3 2025, from $18.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $34.3 million in Q4 2022 and bottomed at $2.3 million in Q1 2021.
• A 5-year average of $14.8 million and a median of $15.1 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2021 — Share-based Compensation soared 323.49% — and 2025, when it retreated 14.74%.
• Year by year, Share-based Compensation stood at $20.2 million in 2021, then soared by 70.34% to $34.3 million in 2022, then slumped by 63.96% to $12.4 million in 2023, then increased by 22.09% to $15.1 million in 2024, then decreased by 0.64% to $15.0 million in 2025.
• The last three Share-based Compensation figures came in at $15.0 million (Q3 2025), $18.7 million (Q2 2025), and $15.9 million (Q1 2025), per Business Quant data.

Peer Comparison